ArticleBMC cancer2025
Multicenter study of CT-based deep learning for predicting preoperative T staging and TNM staging in clear cell renal cell carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- NephroNet: a calibration-aware, patient-disjoint benchmark for multiclass kidney CT classification with a compact depthwise-separable CNN.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundAccurate preoperative T and TNM staging of clear cell renal cell carcinoma (ccRCC) is crucial for diagnosis and treatment, but these assessments often depend on subjective radiologist judgment, leading to interobserver variability. This study aims to design and validate two CT-based deep learning models and evaluate their clinical utility for the preoperative T and TNM staging of ccRCC.
methodsData from 1,148 ccRCC patients across five medical centers were retrospectively collected. Specifically, data from two centers were merged and randomly divided into a training set (80%) and a testing (20%) set. Data from two additional centers comprised external validation set 1, and data from the remaining independent center comprised external validation set 2. Two 3D deep learning models based on a Transformer-ResNet (TR-Net) architecture were developed to predict T staging (T1, T2, T3 + T4) and TNM staging (I, II, III, IV) using corticomedullary phase CT images. Gradient-weighted Class Activation Mapping (Grad-CAM) was used to generate heatmaps for improved model interpretability, and a human-machine collaboration experiment was conducted to evaluate clinical utility. Models' performance was evaluated using micro-average AUC (micro-AUC), macro-average AUC (macro-AUC), and accuracy (ACC).
resultsAcross the two external validation sets, the T staging model achieved micro-AUCs of 0.939 and 0.954, macro-AUCs of 0.857 and 0.894, and ACCs of 0.843 and 0.869, while the TNM staging model achieved micro-AUCs of 0.935 and 0.924, macro-AUCs of 0.817 and 0.888, and ACCs of 0.856 and 0.807. While the models demonstrated acceptable overall performance in preoperative ccRCC staging, performance was moderate for advanced subclasses (T3 + T4 AUC: 0.769 and 0.795; TNM III AUC: 0.669 and 0.801). Grad-CAM heatmaps highlighted key tumor regions, improving interpretability. The human-machine collaboration demonstrated improved diagnostic accuracy with model assistance.
conclusionThe CT-based 3D TR-Net models showed acceptable overall performance with moderate results in advanced subclasses in preoperative ccRCC staging, with interpretable outputs and collaborative benefits, making them potentially useful decision-support tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.